IRulya Therapeutics IRLA
NASDAQ IRLA
$33.78 +2.78 (+8.95%)
At close: Nov 9, 2026 · 4:00 PM EST

IRulya Therapeutics (IRLA) Non Operating Interest Expenses (2018)

Updated

IRulya Therapeutics' Non Operating Interest Expenses came in at $957,000 for FY2018.

Analysis

IRulya Therapeutics (IRLA) Non Operating Interest Expenses (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn -
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 217.00 Mn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn -
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn -
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 269.00 Mn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn -
10 IRulya Therapeutics 207.35 Mn 91.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 358,000.00
Mar 31, 2018 599,000.00
API Access

IRulya Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=IRLA&period=max&api_key=YOUR_API_KEY